A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 7 sites in 3 countries. Open to participants aged 68 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 37th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 3, and was the 19th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 68 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 3 started in 2016.
This study's enrollment of 70 is below the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 33rd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2016, is one of 25 in phase 3, and was the 30th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course. This study will also assess immune responses after re-vaccination with 2 additional doses of the HZ/su administered at ten years after first dose of initial vaccination course from study Zoster-003 (NCT00434577).
In this LTFU study (ZOSTER-060), subjects who received 2 doses of HZ/su in the earlier Zoster-003 (NCT00434577) study will be followed up at Month 108/Year 9 and Month 120/Year 10 post first dose of vaccine for safety and immunogenicity (humoral and cellular). In order to assess the effect of re-vaccination with 2 additional doses of HZ/su vaccine, all the subjects will receive 2 additional doses of the HZ/su vaccine, on a 0, 2-month schedule at ten years after the initial vaccination course in study Zoster-003 (NCT00434577), and will be followed for reactogenicity, safety and humoral and cellular immunogenicity (including persistence).
In alignment with the previous persistence timepoints, this study has no control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
E.g., inactivated and subunit vaccines, including inactivated and subunit influenza vaccines and pneumococcal conjugate vaccines.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
Biological: Herpes Zoster Vaccine GSK1437173A
Intramuscular injection
Also known as: HZ/su
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations
Anti-glycoprotein E (gE) Ab concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micro international units per milliliter (mIU/mL).
Time frame: At Month 108 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations
Anti-gE Ab concentrations were determined by ELISA, presented as GMCs and expressed in mIU/mL.
Time frame: At Month 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.
gE specific CD4 (2+) T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L, were determined by means of Intracellular Cytokine Staining (ICS) and expressed in T-cells/million cells.
Time frame: At Month 108 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells.
gE specific CD4 (2+)T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L were determined by means of ICS and expressed in T-cells/million cells.
Time frame: At Month 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations by Each Age Category
Anti-gE Ab concentrations as determined by ELISA by each age category (60-69 years of age \[YOA\] and ≥70 YOA at the time of initial vaccination).Antibody concentrations were presented as GMCs and expressed in mIU/mL.
Time frame: At Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Frequencies of Antigen-specific CD4 (2+) T-cells by Each Age Category
Antigen specific CD4 (2+) T-cells as determined by means of ICS and expressed in T-cells/million cells, by each age category (60-69 YOA and ≥ 70 YOA at the time of initial vaccination).
Time frame: At Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Number of Subjects With Any Serious Adverse Events (SAEs) Related to Study Participation or to a Concurrent GSK Medication/Vaccine (Including GSK1437173A Administered During the Zoster-003 [NCT00434577] Study).
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Between Months 108 and 120 post first dose of initial vaccination course in study Zoster-003 (NCT00434577).
Anti-gE Specific Antibody (Ab) Concentrations
Anti-gE antibody concentrations were determined by ELISA in all subjects, presented as GMCs and expressed in mIU/mL.
Time frame: At 1 month post each re-vaccination dose (i.e. Month 121 and Month 123) and at 1 year post last re-vaccination dose (i.e., Month 134).
Frequencies of Antigen-specific CD4 (2+) T-cells, Post Re-vaccination Course.
Antigen specific CD4 (2+)T cells were determined by means of ICS and expressed in T-cells/million cells.
Time frame: At 1 month post each re-vaccination dose (i.e. Month 121 and Month 123) and at 1 year post last re-vaccination dose (i.e., Month 134).
Number of Subjects With Any and Grade 3 Solicited Local Symptoms.
Assessed solicited local symptoms included: pain, redness and swelling at injection site. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, prevented normal every day activities. Grade 3 redness/swelling = symptoms spreading beyond a surface of (\>) 100 millimeters (mm).
Time frame: Within 7 days (Days 0-6) after each vaccination and across doses, in the current study.
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.
Assessed solicited general symptoms included: fatigue, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and temperature \[higher than or equal to (≥) 37.5 degrees Celsius (°C) for axillary, oral or tympanic route\] and ≥38.0°C for rectal route. Grade 3 fatigue, gastrointestinal symptoms, headache, myalgia, shivering = symptoms that prevented normal activity. Grade 3 temperature = defined as fever higher than (\>) 39.0°C, regardless of the route used.
Time frame: Within 7 days (Days 0-6) after each vaccination and across doses, in the current study.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) According to the Medical Dictionary for Regulatory Activities (MedDRA) Classification in All Subjects.
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within 30 days (Days 0-29) after each vaccination in the current study.
Number of Subjects With Any, Related and Fatal SAEs.
SAEs assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
Time frame: From Dose 1 of re-vaccination (Month 120) until study end (Month 134).
Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs).
pIMDs assessed includes AEs that were autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related pIMDs= pIMDs assessed by the investigator as related to the vaccination.
Time frame: From Dose 1 of re-vaccination (Month 120) until study end (Month 134).
Subjects who participated in the parent study Zoster-003 (NCT00434577),in GSK1437173A _MD Group and received a complete vaccination course(2 doses of 50 µg GSK1437173A) were offered participation in this Long Term Follow-Up study. A total of 70 subjects met the eligibility criteria \& consented to participate in Germany, Sweden and Czech Republic
| Milestone | GSK1437173A Vaccine Group |
|---|---|
| Started | 70 |
| Vaccinated | 62 |
| Completed | 59 |
| Not completed | 11 |
| Withdrew: Not vaccinated but subject id assigned | 8 |
| Withdrew: Withdrawal following sae | 2 |
| Withdrew: Withdrawal by subject | 1 |
Anti-glycoprotein E (gE) Ab concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micro international units per milliliter (mIU/mL).
| mIU/mL | GSK1437173A Vaccine Group |
|---|---|
| Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations | 9122.9 (7775.2 to 10704.1) |
Anti-gE Ab concentrations were determined by ELISA, presented as GMCs and expressed in mIU/mL.
| mIU/mL | GSK1437173A Vaccine Group |
|---|---|
| Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations | 7384.0 (6202.8 to 8790.1) |
gE specific CD4 (2+) T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L, were determined by means of Intracellular Cytokine Staining (ICS) and expressed in T-cells/million cells.
| CD4 T-cells/million cells | GSK1437173A Vaccine Group |
|---|---|
| Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells. | 414.0 (220.9 to 796.5) |
gE specific CD4 (2+)T-cells expressing at least 2 activation markers among IFN-γ, IL-2, TNF-α and CD40L were determined by means of ICS and expressed in T-cells/million cells.
| CD4 T-cells/million cells | GSK1437173A Vaccine Group |
|---|---|
| Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells. | 401.9 (298.1 to 901.9) |
Anti-gE Ab concentrations as determined by ELISA by each age category (60-69 years of age \[YOA\] and ≥70 YOA at the time of initial vaccination).Antibody concentrations were presented as GMCs and expressed in mIU/mL.
| mIU/mL | GSK1437173A Vaccine 60-69 YOA Sub-group | GSK1437173A Vaccine ≥ 70 YOA Sub-group |
|---|---|---|
| Anti-gE, Month 108 | 8566.4 (5697.1 to 12880.9) | 9259.6 (7741.6 to 11075.2) |
| Anti-gE, Month 120 | 7401.4 (4894.2 to 11193.1) | 7380.2 (6048.9 to 9004.4) |
Antigen specific CD4 (2+) T-cells as determined by means of ICS and expressed in T-cells/million cells, by each age category (60-69 YOA and ≥ 70 YOA at the time of initial vaccination).
| CD4 T-cells/million cells | GSK1437173A Vaccine 60-69 YOA Sub-group | GSK1437173A Vaccine ≥ 70 YOA Sub-group |
|---|---|---|
| CD4(2+), Month 108 | 453.8 (233.2 to 577.6) | 398.9 (220.9 to 811.3) |
| CD4(2+), Month 120 | 359.2 (254.9 to 885.0) | 429.4 (298.1 to 940.1) |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A Vaccine Group |
|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs) Related to Study Participation or to a Concurrent GSK Medication/Vaccine (Including GSK1437173A Administered During the Zoster-003 [NCT00434577] Study). | 0 |
Anti-gE antibody concentrations were determined by ELISA in all subjects, presented as GMCs and expressed in mIU/mL.
| mIU/mL | GSK1437173A Vaccine Group |
|---|---|
| Anti-gE, Month 121 | 108199.6 (87154.2 to 134326.8) |
| Anti-gE, Month 123 | 90003.6 (76754.3 to 105539.9) |
| Anti-gE, Month 134 | 30066.2 (25810.3 to 35023.8) |
Antigen specific CD4 (2+)T cells were determined by means of ICS and expressed in T-cells/million cells.
| CD4 T-cells/million cells | GSK1437173A Vaccine Group |
|---|---|
| CD4(2+), Month 121 | 2563.9 (1219.9 to 4127.4) |
| CD4(2+), Month 123 | 1775.5 (1181.4 to 3077.8) |
| CD4(2+), Month 134 | 1196.3 (680.8 to 1850.8) |
Assessed solicited local symptoms included: pain, redness and swelling at injection site. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, prevented normal every day activities. Grade 3 redness/swelling = symptoms spreading beyond a surface of (\>) 100 millimeters (mm).
| Participants | GSK1437173A Vaccine Group |
|---|---|
| Any Pain, Dose 1 | 41 |
| Grade 3 Pain, Dose 1 | 1 |
| Any Redness, Dose 1 | 19 |
| >100 mm Redness, Dose 1 | 0 |
| Any Swelling, Dose 1 | 11 |
| >100 mm Swelling, Dose 1 | 0 |
| Any Pain, Dose 2 | 26 |
| Grade 3 Pain, Dose 2 | 2 |
| Any Redness, Dose 2 | 17 |
| >100 mm Redness, Dose 2 | 0 |
| Any Swelling, Dose 2 | 7 |
| >100 mm Swelling, Dose 2 | 0 |
| Any Pain, Across doses | 46 |
| Grade 3 Pain, Across doses | 2 |
| Any Redness, Across doses | 27 |
| >100 mm Redness, Across doses | 0 |
| Any Swelling, Across doses | 16 |
| > 100 mm Swelling, Across doses | 0 |
Assessed solicited general symptoms included: fatigue, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and temperature \[higher than or equal to (≥) 37.5 degrees Celsius (°C) for axillary, oral or tympanic route\] and ≥38.0°C for rectal route. Grade 3 fatigue, gastrointestinal symptoms, headache, myalgia, shivering = symptoms that prevented normal activity. Grade 3 temperature = defined as fever higher than (\>) 39.0°C, regardless of the route used.
| Participants | GSK1437173A Vaccine Group |
|---|---|
| Any Fatigue, Dose 1 | 25 |
| Grade 3 Fatigue, Dose 1 | 3 |
| Related Fatigue, Dose 1 | 25 |
| Any Gastrointestinal symptoms, Dose 1 | 7 |
| Grade 3 Gastrointestinal symptoms, Dose 1 | 0 |
| Related Gastrointestinal symptoms, Dose 1 | 7 |
| Any Headache, Dose 1 | 12 |
| Grade 3 Headache, Dose 1 | 3 |
| Related Headache, Dose 1 | 12 |
| Any Myalgia, Dose 1 | 20 |
| Grade 3 Myalgia, Dose 1 | 1 |
| Related Myalgia, Dose 1 | 19 |
| Any Shivering, Dose 1 | 12 |
| Grade 3 Shivering, Dose 1 | 2 |
| Related Shivering, Dose 1 | 12 |
| Any Temperature, Dose 1 | 9 |
| >39.0°C Temperature, Dose 1 | 0 |
| Related Temperature, Dose 1 | 8 |
| Any Fatigue, Dose 2 | 15 |
| Grade 3 Fatigue, Dose 2 | 1 |
| Related Fatigue, Dose 2 | 14 |
| Any Gastrointestinal symptoms, Dose 2 | 7 |
| Grade 3 Gastrointestinal symptoms, Dose 2 | 0 |
| Related Gastrointestinal symptoms, Dose 2 | 5 |
| Any Headache, Dose 2 | 12 |
| Grade 3 Headache, Dose 2 | 1 |
| Related Headache, Dose 2 | 12 |
| Any Myalgia, Dose 2 | 15 |
| Grade 3 Myalgia, Dose 2 | 2 |
| Related Myalgia, Dose 2 | 14 |
| Any Shivering, Dose 2 | 8 |
| Grade 3 Shivering, Dose 2 | 2 |
| Related Shivering, Dose 2 | 8 |
| Any Temperature, Dose 2 | 8 |
| >39.0°C Temperature, Dose 2 | 0 |
| Related Temperature, Dose 2 | 7 |
| Any Fatigue, Across doses | 31 |
| Grade 3 Fatigue, Across doses | 3 |
| Related Fatigue, Across doses | 31 |
| Any Gastrointestinal symptoms, Across doses | 11 |
| Grade 3 Gastrointestinal symptoms, Across doses | 0 |
| Related Gastrointestinal symptoms, Across doses | 10 |
| Any Headache, Across doses | 18 |
| Grade 3 Headache, Across doses | 4 |
| Related Headache, Across doses | 18 |
| Any Myalgia, Across doses | 29 |
| Grade 3 Myalgia, Across doses | 3 |
| Related Myalgia, Across doses | 27 |
| Any Shivering, Across doses | 16 |
| Grade 3 Shivering, Across doses | 4 |
| Related Shivering, Across doses | 16 |
| Any Temperature, Across doses | 15 |
| >39.0°C Temperature, Across doses | 0 |
| Related Temperature, Across doses | 13 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Vaccine Group |
|---|---|
| Any AEs | 14 |
| Any Grade 3 AEs | 1 |
| Any Related AEs | 5 |
SAEs assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
| Participants | GSK1437173A Vaccine Group |
|---|---|
| Any SAEs | 7 |
| Related SAEs | 0 |
| Any Fatal SAEs | 0 |
pIMDs assessed includes AEs that were autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related pIMDs= pIMDs assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Vaccine Group |
|---|---|
| Any pIMDs | 0 |
| Related pIMDs | 0 |
Collected over Solicited symptoms: During the 7 day (Day 0-6) post vaccination. Unsolicited symptoms: during the 30-day (Days 0-29) post-vaccination period; SAEs: From study start (Month 108) up to study end (Month 134).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Vaccine Group | 0/62 (0%) | 7/62 (11.3%) | 53/62 (85.5%) |
| Event | GSK1437173A Vaccine Group |
|---|---|
| Acute myocardial infarctionCardiac disorders | 1/62 |
| Atrial fibrillationCardiac disorders | 1/62 |
| Atrial flutterCardiac disorders | 1/62 |
| Atrial tachycardiaCardiac disorders | 1/62 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 1/62 |
| Retroperitoneal haematomaGastrointestinal disorders | 1/62 |
| Cholecystitis acuteHepatobiliary disorders | 1/62 |
| Septic shockInfections and infestations | 1/62 |
| Cerebrovascular accidentNervous system disorders | 1/62 |
| Event | GSK1437173A Vaccine Group |
|---|---|
| PainGeneral disorders | 46/62 |
| FatigueGeneral disorders | 31/62 |
| MyalgiaMusculoskeletal and connective tissue disorders | 29/62 |
| ErythemaSkin and subcutaneous tissue disorders | 27/62 |
| HeadacheNervous system disorders | 18/62 |
| ChillsGeneral disorders | 16/62 |
| SwellingGeneral disorders | 16/62 |
| PyrexiaGeneral disorders | 15/62 |
| Gastrointestinal disorderGastrointestinal disorders | 11/62 |
| NauseaGastrointestinal disorders | 1/62 |
| Age, Continuous(Years) | GSK1437173A Vaccine Group |
|---|---|
| Mean | 72.3 ± 4.3 |
| Sex: Female, Male(Participants) | GSK1437173A Vaccine Group |
|---|---|
| Female | 43 |
| Male | 27 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Vaccine Group |
|---|---|
| White-Caucasian/European Heritage | 70 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Apr 2016 to primary completion in Aug 2017, 16 months.
Results were first posted in Nov 2019, 2 years 2 months after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 16 months is close to that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix